DGAP-News: Epigenomics AG Reports Financial Results for the First Quarter of 2021
For this purpose, a corresponding sales process has been set up and the Company is in discussions with several potential parties.
DGAP-News: Epigenomics AG / Key word(s): Quarterly / Interim Statement/Quarter Results Epigenomics AG Reports Financial Results for the First Quarter of 2021 12.05.2021 / 08:00 The issuer is solely responsible for the content of this announcement. Press release Epigenomics AG Reports Financial Results for the First Quarter of 2021 Berlin (Germany) and San Diego, CA (U.S.A.), May 12, 2021 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first three months of 2021. Financial key figures
Strategic options Following the negative reimbursement decision by the CMS in January 2021, the management is considering various strategic options. As announced at the end of March, the Company is evaluating, among other things, a potential sale of the Company by way of a share deal (public takeover) or asset deal to one or more investors as part of an M&A transaction. For this purpose, a corresponding sales process has been set up and the Company is in discussions with several potential parties. The Company has mandated a leading international investment bank as advisor in connection with the sale process. Major events after the end of the reporting period
Outlook 2021 Revenue
EBITDA / Cash consumption
Further Information The 2020 Q1 interim statement (unaudited) is available on the Epigenomics' website: https://www.epigenomics.com/news-investors/financial-reports/. Conference call for analysts and investors Epigenomics AG will host a conference call for analysts and investors today at 5.00 pm (CET) / 11.00 am (EDT). The webcast can be accessed on the Company's website: https://www.epigenomics.com/news-investors/financial-reports/. The dial-in numbers for the conference call are: Dial-in number Germany: +49 30 232531508 Participants are asked to dial in 10 minutes prior to the start of the conference call and to register using the link above. An audio replay of the conference call will be provided on the Epigenomics' website subsequently. About Epigenomics For further information please visit www.epigenomics.com. Contact: Investor Relations
Note on forward-looking statements This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG's actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.
12.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Epigenomics AG |
Geneststraße 5 | |
10829 Berlin | |
Germany | |
Phone: | +49 30 24345-0 |
Fax: | +49 30 24345-555 |
E-mail: | [email protected] |
Internet: | www.epigenomics.com |
ISIN: | DE000A3H2184 |
WKN: | A3H218 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1195463 |
End of News | DGAP News Service |
|
1195463 12.05.2021